When the Conversation Never Stops: How Broken Signalling Fuels Cancer

Every cell in the human body is engaged in a constant exchange of messages. Growth factors arrive, receptors relay their instructions, and enzymes cascade the signal onwards until the cell knows precisely what to do: divide, differentiate, or hold still. Cancer, viewed through the lens of cell signalling, is not simply cells multiplying too quickly. It is a communication system that has lost its off switch.

The Normal Conversation: Receptors as Gatekeepers

Consider the epidermal growth factor receptor, or EGFR. In healthy tissue, this receptor sits quietly in the plasma membrane until a matching ligand binds from outside. That binding event triggers dimerisation, activates the intracellular kinase domains, and sets off a phosphorylation cascade. The signal is precise, transient, and self-limiting. Once the ligand is gone, phosphatases strip away the phosphate groups, and the pathway falls silent.

This restraint matters. Cell division in a healthy epithelium — the lining of the airways, the gut, the skin — is tightly matched to tissue need. Signalling pathways are the machinery that enforces that match.

When the Receptor Refuses to Listen to Silence

Now imagine the same receptor with a mutation in the gene that encodes it. In many non-small cell lung cancers — a disease that claims over 34,000 lives in the UK each year, according to Cancer Research UK — deletions or point substitutions in the EGFR gene produce a receptor that dimerises and phosphorylates without any ligand at all. The gatekeeper has become a megaphone.

From this single molecular fault, the consequences cascade. A constitutively active EGFR continuously engages its downstream partners, chief among them the RAS–ERK pathway. RAS, a small GTP-binding protein, normally toggles between an 'on' state (bound to GTP) and an 'off' state (bound to GDP). Its own intrinsic timer, aided by GTPase-activating proteins, ensures the on-state is fleeting.

But a single amino acid change — most famously at position 12 of the RAS protein — locks the molecule in its GTP-bound form. The timer is broken. ERK signalling, which instructs the cell to progress through the cell cycle, remains permanently engaged. The cell receives an unambiguous, unceasing instruction: divide.

From a Single Fault to a Tumour

It is tempting to imagine that one sticky switch is sufficient to cause cancer, but the reality is more gradual. Sustained ERK signalling drives proliferation, yet the body retains safeguards: checkpoint proteins such as p53 can halt a rogue cell, and overcrowding signals can restrain growth. This is why tumorigenesis typically requires the accumulation of multiple lesions over years or decades — a concept formalised in the classic multi-step model of carcinogenesis.

Each additional hit compounds the communication failure. Loss of p53 removes the emergency brake. Activation of PI3K–AKT signalling, often through loss of the tumour suppressor PTEN, tells the cell that nutrients are abundant and apoptosis should be postponed. The result is a clone of cells that no longer responds to any of the normal conversational cues — contact inhibition, growth factor dependence, or internal quality control.

UK Research: From Mechanism to Medicine

British research institutions have been central to translating this understanding into therapies. The Institute of Cancer Research in London pioneered work on kinase inhibitors that would ultimately shape modern oncology. AstraZeneca, headquartered in Cambridge, developed osimertinib, a third-generation EGFR inhibitor designed to target the mutant receptors of non-small cell lung cancer while sparing the wild-type receptor — a direct pharmacological exploitation of the difference between a healthy signal and a hijacked one.

Similarly, the discovery that RAS was once considered 'undruggable' has given way to progress. The approval of sotorasib and adagrasib for tumours bearing the KRAS G12C mutation demonstrated that even the most intractable signalling defect can be addressed when its biochemistry is fully understood.

Why the Signalling View Matters

Framing cancer as a signalling disease does more than satisfy intellectual curiosity. It explains why targeted therapies work, why resistance emerges (tumours frequently rewire around a blocked pathway, rerouting through parallel cascades such as MET bypass signalling), and why combination treatments are increasingly the norm.

For students, the lesson is one of scale. A tumour visible on a scan begins as a single mis-phosphorylated protein, an argument between a receptor and the rules of the pathway it belongs to. Understanding that conversation — and learning to interrupt it selectively — remains one of the most powerful ideas in modern medicine.